Quantitation and characterization of glucosylsphingosine in cerebrospinal fluid (CSF), plasma, and brain of monkey model with Gaucher disease
Open Access
- 15 September 2023
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 53, 100530
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Progressive decline of glucocerebrosidase in aging and P arkinson's diseaseAnnals of Clinical and Translational Neurology, 2015
- Gaucher disease: Plasmalogen levels in relation to primary lipid abnormalities and oxidative stressBlood Cells, Molecules, and Diseases, 2014
- Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease PatientsPLOS ONE, 2013
- Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathiesProceedings of the National Academy of Sciences of the United States of America, 2013
- Animal models for Gaucher disease researchDisease Models & Mechanisms, 2011
- Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic responseBlood, 2011
- Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic interventionBlood, 2004
- Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.Journal of Clinical Investigation, 1994
- THE GAUCHER MOUSE: DIFFERENTIAL ACTION OF CONDURITOL B EPOXIDE AND REVERSIBILITY OF ITS EFFECTSJournal of Neurochemistry, 1978
- The Gaucher mouseBiochemical and Biophysical Research Communications, 1975